Clinical Scorecard: Assessment of T-cell Immune Responses Following mRNA-1273 Vaccination in Pediatric Patients Aged 6 Months to 11 Years
At a Glance
Category
Detail
Condition
COVID-19 caused by SARS-CoV-2 infection
Key Mechanisms
Induction of SARS-CoV-2 spike protein-specific Th1-biased CD4+ T-cell responses and variable CD8+ T-cell responses
Target Population
Pediatric patients aged 6 months to 11 years
Care Setting
Outpatient vaccination and clinical trial settings
Key Highlights
mRNA-1273 vaccination induces robust and durable Th1-biased CD4+ T-cell responses in children aged 6 months to 11 years.
CD8+ T-cell responses are less frequent in children under 5 years and undetectable in those under 2 years.
T-cell responses correlate with neutralizing antibody levels and may contribute to protection against SARS-CoV-2 variants.
Guideline-Based Recommendations
Diagnosis
Assessment of SARS-CoV-2 infection risk in pediatric populations to guide vaccination.
Management
Administer 2-dose primary series of mRNA-1273 vaccine: 25 µg for ages 6 months to 5 years, 50 µg for ages 6 to 11 years, 28 days apart.
Monitoring & Follow-up
Monitor T-cell immune responses and neutralizing antibody levels post-vaccination to evaluate durability and inform booster timing.
Risks
Consider age-dependent variability in CD8+ T-cell responses when evaluating immune protection in younger children.
Patient & Prescribing Data
Children aged 6 months to 11 years enrolled in the phase 2/3 KidCOVE trial
Two doses of mRNA-1273 vaccine elicit strong Th1-biased CD4+ T-cell responses lasting at least 6 months, with acceptable safety and immunogenicity profiles.
Clinical Best Practices
Use age-appropriate dosing of mRNA-1273 vaccine to optimize immune response in pediatric patients.
Consider both humoral and cell-mediated immunity when assessing vaccine efficacy and protection.
Include children with stable chronic conditions in vaccination programs to ensure broad protection.
Obtain informed consent and assent according to ethical guidelines before vaccination and study participation.
by Christina A Rostad, James D Campbell, Grant C Paulsen, Sabine Schnyder Ghamloush, Wenqin Xu, Lingyi Zheng, M Juliana McElrath, Stephen C De Rosa, Bethany Girard, Rituparna Das, Evan J Anderson, C Buddy Creech, on behalf of the KidCOVE CMI Study Group
